SightfileU.S. market data from official filings

ERASCA INC (ERAS)

Name: ERASCA INC (ERAS) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001761918 · EDGAR filings · Updated 2026-07-21

ERASCA INC (ERAS) has reported institutional ownership of 88.0%, with 224 institutional managers holding positions valued at $4.39B per the latest 13F reporting period.

Institutional ownership

88.0%

Institutional managers

224

Reported 13F value

$4.39B

Insider activity

8 trans.

−$971.6K net selling

Latest updates

2026-07-21 — Notice of proposed sale filed (Form 144)
2026-07-14 — Current report (8-K) filed
2026-07-14 — Prospectus supplement (424B5) filed
2026-07-13 — Prospectus supplement (424B5) filed
2026-07-13 — Current report (8-K) filed
2026-07-13 — S-3ASR filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, ERASCA INC has 224 institutional holders and institutional ownership of 88.0%.

Insider activity

Insiders reported 8 transactions (0 buys, 2 sells) across 4 reporting insiders, with a net reported value of −$971.6K.

Related companies

ENVISTA HOLDINGS CORPORATION (NVST) · CRINETICS PHARMACEUTICALS IN (CRNX) · OPTION CARE HEALTH INC (OPCH) · RADNET INC (RDNT) · IRHYTHM HOLDINGS INC (IRTC) · SPYRE THERAPEUTICS INC (SYRE)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-21.